A citation-based method for searching scientific literature

Martin Kolb, Luca Richeldi, Jürgen Behr, Toby M Maher, Wenbo Tang, Susanne Stowasser, Christoph Hallmann, Roland M du Bois. Thorax 2017
Times Cited: 121







List of co-cited articles
901 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Luca Richeldi, Roland M du Bois, Ganesh Raghu, Arata Azuma, Kevin K Brown, Ulrich Costabel, Vincent Cottin, Kevin R Flaherty, David M Hansell, Yoshikazu Inoue,[...]. N Engl J Med 2014
77

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.
Ganesh Raghu, Harold R Collard, Jim J Egan, Fernando J Martinez, Juergen Behr, Kevin K Brown, Thomas V Colby, Jean-François Cordier, Kevin R Flaherty, Joseph A Lasky,[...]. Am J Respir Crit Care Med 2011
57

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Talmadge E King, Williamson Z Bradford, Socorro Castro-Bernardini, Elizabeth A Fagan, Ian Glaspole, Marilyn K Glassberg, Eduard Gorina, Peter M Hopkins, David Kardatzke, Lisa Lancaster,[...]. N Engl J Med 2014
56

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.
Ganesh Raghu, Bram Rochwerg, Yuan Zhang, Carlos A Cuello Garcia, Arata Azuma, Juergen Behr, Jan L Brozek, Harold R Collard, William Cunningham, Sakae Homma,[...]. Am J Respir Crit Care Med 2015
39

Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS.
Ulrich Costabel, Yoshikazu Inoue, Luca Richeldi, Harold R Collard, Inga Tschoepe, Susanne Stowasser, Arata Azuma. Am J Respir Crit Care Med 2016
157
39

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Ganesh Raghu, Martine Remy-Jardin, Jeffrey L Myers, Luca Richeldi, Christopher J Ryerson, David J Lederer, Juergen Behr, Vincent Cottin, Sonye K Danoff, Ferran Morell,[...]. Am J Respir Crit Care Med 2018
39

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
Luca Richeldi, Ulrich Costabel, Moises Selman, Dong Soon Kim, David M Hansell, Andrew G Nicholson, Kevin K Brown, Kevin R Flaherty, Paul W Noble, Ganesh Raghu,[...]. N Engl J Med 2011
663
37

Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function.
Carlo Albera, Ulrich Costabel, Elizabeth A Fagan, Marilyn K Glassberg, Eduard Gorina, Lisa Lancaster, David J Lederer, Steven D Nathan, Dominique Spirig, Jeff J Swigris. Eur Respir J 2016
92
38

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Paul W Noble, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Marilyn K Glassberg, David Kardatzke, Talmadge E King, Lisa Lancaster, Steven A Sahn, Javier Szwarcberg,[...]. Lancet 2011
31

Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.
Luca Richeldi, Vincent Cottin, Roland M du Bois, Moisés Selman, Toshio Kimura, Zelie Bailes, Rozsa Schlenker-Herceg, Susanne Stowasser, Kevin K Brown. Respir Med 2016
223
31

Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.
Harold R Collard, Christopher J Ryerson, Tamera J Corte, Gisli Jenkins, Yasuhiro Kondoh, David J Lederer, Joyce S Lee, Toby M Maher, Athol U Wells, Katerina M Antoniou,[...]. Am J Respir Crit Care Med 2016
588
27

Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Ganesh Raghu, Kevin J Anstrom, Talmadge E King, Joseph A Lasky, Fernando J Martinez. N Engl J Med 2012
923
27

Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper.
David A Lynch, Nicola Sverzellati, William D Travis, Kevin K Brown, Thomas V Colby, Jeffrey R Galvin, Jonathan G Goldin, David M Hansell, Yoshikazu Inoue, Takeshi Johkoh,[...]. Lancet Respir Med 2018
416
26

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Lutz Wollin, Eva Wex, Alexander Pautsch, Gisela Schnapp, Katrin E Hostettler, Susanne Stowasser, Martin Kolb. Eur Respir J 2015
379
25

Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria.
Ganesh Raghu, Athol U Wells, Andrew G Nicholson, Luca Richeldi, Kevin R Flaherty, Florence Le Maulf, Susanne Stowasser, Rozsa Schlenker-Herceg, David M Hansell. Am J Respir Crit Care Med 2017
108
24

Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis.
Harold R Collard, Luca Richeldi, Dong Soon Kim, Hiroyuki Taniguchi, Inga Tschoepe, Maurizio Luisetti, Jesse Roman, Gregory Tino, Rozsa Schlenker-Herceg, Christoph Hallmann,[...]. Eur Respir J 2017
73
30

Clinical course and prediction of survival in idiopathic pulmonary fibrosis.
Brett Ley, Harold R Collard, Talmadge E King. Am J Respir Crit Care Med 2011
914
21

Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.
Bruno Crestani, John T Huggins, Mitchell Kaye, Ulrich Costabel, Ian Glaspole, Takashi Ogura, Jin Woo Song, Wibke Stansen, Manuel Quaresma, Susanne Stowasser,[...]. Lancet Respir Med 2019
84
25

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.
Paul W Noble, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Roland M du Bois, Elizabeth A Fagan, Robert S Fishman, Ian Glaspole, Marilyn K Glassberg, Lisa Lancaster,[...]. Eur Respir J 2016
223
19

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
Carlo Vancheri, Michael Kreuter, Luca Richeldi, Christopher J Ryerson, Dominique Valeyre, Jan C Grutters, Sabrina Wiebe, Wibke Stansen, Manuel Quaresma, Susanne Stowasser,[...]. Am J Respir Crit Care Med 2018
110
19


BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
Frank Hilberg, Gerald J Roth, Martin Krssak, Susanna Kautschitsch, Wolfgang Sommergruber, Ulrike Tontsch-Grunt, Pilar Garin-Chesa, Gerd Bader, Andreas Zoephel, Jens Quant,[...]. Cancer Res 2008
704
18

A multidimensional index and staging system for idiopathic pulmonary fibrosis.
Brett Ley, Christopher J Ryerson, Eric Vittinghoff, Jay H Ryu, Sara Tomassetti, Joyce S Lee, Venerino Poletti, Matteo Buccioli, Brett M Elicker, Kirk D Jones,[...]. Ann Intern Med 2012
626
18

Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.
Helen E Jo, Ian Glaspole, Christopher Grainge, Nicole Goh, Peter M A Hopkins, Yuben Moodley, Paul N Reynolds, Sally Chapman, E Haydn Walters, Christopher Zappala,[...]. Eur Respir J 2017
111
17

Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.
Steven D Nathan, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Ian Glaspole, Marilyn K Glassberg, David R Kardatzke, Monica Daigl, Klaus-Uwe Kirchgaessler, Lisa H Lancaster,[...]. Lancet Respir Med 2017
151
16

Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome.
J W Song, S-B Hong, C-M Lim, Y Koh, D S Kim. Eur Respir J 2011
444
16

Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review.
John Hutchinson, Andrew Fogarty, Richard Hubbard, Tricia McKeever. Eur Respir J 2015
367
16

Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11.
Ganesh Raghu, Shih-Yin Chen, Wei-Shi Yeh, Brad Maroni, Qian Li, Yuan-Chi Lee, Harold R Collard. Lancet Respir Med 2014
332
16

Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions.
Jonathan A Galli, Aloknath Pandya, Michelle Vega-Olivo, Chandra Dass, Huaqing Zhao, Gerard J Criner. Respirology 2017
91
17

An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
William D Travis, Ulrich Costabel, David M Hansell, Talmadge E King, David A Lynch, Andrew G Nicholson, Christopher J Ryerson, Jay H Ryu, Moisés Selman, Athol U Wells,[...]. Am J Respir Crit Care Med 2013
16

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis.
Tamera Corte, Francesco Bonella, Bruno Crestani, Maurits G Demedts, Luca Richeldi, Carl Coeck, Katy Pelling, Manuel Quaresma, Joseph A Lasky. Respir Res 2015
76
19

Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
Lutz Wollin, Isabelle Maillet, Valérie Quesniaux, Alexander Holweg, Bernhard Ryffel. J Pharmacol Exp Ther 2014
323
15

Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.
Brett Ley, Jeffrey Swigris, Bann-Mo Day, John L Stauffer, Karina Raimundo, Willis Chou, Harold R Collard. Am J Respir Crit Care Med 2017
88
17

Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis.
Martin Kolb, Ganesh Raghu, Athol U Wells, Jürgen Behr, Luca Richeldi, Birgit Schinzel, Manuel Quaresma, Susanne Stowasser, Fernando J Martinez. N Engl J Med 2018
112
15

Pirfenidone in idiopathic pulmonary fibrosis.
H Taniguchi, M Ebina, Y Kondoh, T Ogura, A Azuma, M Suga, Y Taguchi, H Takahashi, K Nakata, A Sato,[...]. Eur Respir J 2010
623
14

Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis.
Michael Kreuter, Wim Wuyts, Elisabetta Renzoni, Dirk Koschel, Toby M Maher, Martin Kolb, Derek Weycker, Paolo Spagnolo, Klaus-Uwe Kirchgaessler, Felix J F Herth,[...]. Lancet Respir Med 2016
127
14

Idiopathic pulmonary fibrosis.
Luca Richeldi, Harold R Collard, Mark G Jones. Lancet 2017
573
14

Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis.
Francesco Bonella, Michael Kreuter, Lars Hagmeyer, Claus Neurohr, Claus Keller, Martin J Kohlhaeufl, Joachim Müller-Quernheim, Katrin Milger, Antje Prasse. Respiration 2016
41
34

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis.
Andreas Guenther, Ekaterina Krauss, Silke Tello, Jasmin Wagner, Bettina Paul, Stefan Kuhn, Olga Maurer, Sabine Heinemann, Ulrich Costabel, María Asunción Nieto Barbero,[...]. Respir Res 2018
124
14

Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis.
Takashi Ogura, Hiroyuki Taniguchi, Arata Azuma, Yoshikazu Inoue, Yasuhiro Kondoh, Yoshinori Hasegawa, Masashi Bando, Shinji Abe, Yoshiro Mochizuki, Kingo Chida,[...]. Eur Respir J 2015
115
13

Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry.
Michael Kreuter, Jeff Swigris, David Pittrow, Silke Geier, Jens Klotsche, Antje Prasse, Hubert Wirtz, Dirk Koschel, Stefan Andreas, Martin Claussen,[...]. Respir Res 2017
85
15

Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review.
Ganesh Raghu, Valeria C Amatto, Jürgen Behr, Susanne Stowasser. Eur Respir J 2015
201
13

Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.
Fernando J Martinez, Joao A de Andrade, Kevin J Anstrom, Talmadge E King, Ganesh Raghu. N Engl J Med 2014
302
12

Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis.
Gareth Hughes, Hannah Toellner, Helen Morris, Colm Leonard, Nazia Chaudhuri. J Clin Med 2016
97
12

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.
Steven D Nathan, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Roland M du Bois, Elizabeth A Fagan, Robert S Fishman, Ian Glaspole, Marilyn K Glassberg, Kenneth F Glasscock,[...]. Thorax 2016
102
12

Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
Eva Brunnemer, Julia Wälscher, Svenja Tenenbaum, Julia Hausmanns, Karen Schulze, Marianne Seiter, Claus Peter Heussel, Arne Warth, Felix J F Herth, Michael Kreuter. Respiration 2018
42
28

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Oliver Distler, Kristin B Highland, Martina Gahlemann, Arata Azuma, Aryeh Fischer, Maureen D Mayes, Ganesh Raghu, Wiebke Sauter, Mannaig Girard, Margarida Alves,[...]. N Engl J Med 2019
461
12

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Kevin R Flaherty, Athol U Wells, Vincent Cottin, Anand Devaraj, Simon L F Walsh, Yoshikazu Inoue, Luca Richeldi, Martin Kolb, Kay Tetzlaff, Susanne Stowasser,[...]. N Engl J Med 2019
522
12

Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.
Joyce S Lee, Harold R Collard, Kevin J Anstrom, Fernando J Martinez, Imre Noth, Rhonda S Roberts, Eric Yow, Ganesh Raghu. Lancet Respir Med 2013
247
11



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.